Tavolixizumab (anti-CD134)

COA

级别和纯度:

≥95%(SDS-PAGE&SEC-HPLC)
见COA

应用:

Animal Model
ELISA
Flow Cytometry
Functional Assay

宿主种属: 人(Human)
种属反应性: 人(Human)
亚型: Human IgG1
偶联: Unconjugated

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
Ab182830-100μg	100μg	现货
Ab182830-1mg	1mg	现货
Ab182830-5mg	5mg	现货
Ab182830-10mg	10mg	期货

查看相关系列

点击查看靶蛋白信息: TNFRSF4

Accession#:P43489 (10) CD134 (11) Extrinsic Pathway (1228) Gene ID:7293 (10) OX40 (11) Tnfrsf4 (11)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Tavolixizumab (anti-CD134)
别名	他利昔珠单抗 \| 他沃利珠单抗(抗 CD134)
英文别名	ACT 35 antibody \| ACT35 antibody \| ACT35 antigen antibody \| ATC35 antigen antibody \| CD 134 antibody \| CD134 antibody \| CD134 antigen antibody \| IMD16 antibody \| Lymphoid activation antigene ACT35 antibody \| OX 40 antibody \| OX40 antibody \| OX40 antigen a
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	TNFRSF4
种属反应性	人(Human)
偶联	Unconjugated

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	26.7 kDa (Light Chain) & 51.3 kDa (Heavy Chain), under reducing conditions; 196.3 kDa, under non-reducing conditions.
纯化方法	Protein A purified
物理外观	Liquid
储存缓冲液	Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	1635395-25-3
分子类型	抗体

关联靶点（人）

TNFRSF4 Tchem 肿瘤坏死因子受体超家族成员 4(Tumor necrosis factor receptor superfamily member 4) (0 活性数据)

点击查看靶蛋白信息： TNFRSF4

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

Flow Cytometry: Tavolixizumab (anti-CD134) (Ab182830)

Tavolixizumab (anti-CD134) (Ab182830) - Flow Cytometry
Flow Cytometry analysis of Jurkat cells labelling CD134 (red) with Tavolixizumab (anti-CD134) (Ab182830). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Flow Cytometry: Tavolixizumab (anti-CD134) (Ab182830)

Tavolixizumab (anti-CD134) (Ab182830) - Flow Cytometry
OX40-NF-κB-Jurkat were stained with tavolimab (anti-CD134) (Ab182830) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC₅₀ is 0.053 μg/mL.

SEC: Tavolixizumab (anti-CD134) (Ab182830)

Tavolixizumab (anti-CD134) (Ab182830) - SEC
The purity of Tavolixizumab (anti-CD134) (Ab182830) is more than 95% verified by HPLC.

ELISA: Tavolixizumab (anti-CD134) (Ab182830)

Tavolixizumab (anti-CD134) (Ab182830) - ELISA
Immobilized Recombinant Human OX40/TNFRSF4 Protein (rp181285) at 1.0 μg/mL can bind Tavolixizumab (anti-CD134) (Ab182830) with the EC₅₀ of 41.2 ng/mL.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到3个结果